
category:watercooler
Shortages threaten corporate profits, likely to end soon
We think the GLP1 shortage is going to end in the first half of 2025. Here's why.
category:watercooler
We think the GLP1 shortage is going to end in the first half of 2025. Here's why.
category:news
The FDA has approved Semaglutide for chronic kidney disease. We explore research and the possible implications for insurance coverage and more.
government
The government has selected Ozempic and Wegovy for price negotiations -- are we going to see cheaper prices?
category:benefits
Center for Medicare and Medicaid declared that Zepbound is covered by insurance for treating Sleep Apnea, given it's effectiveness.
categeory:watercooler
We debunk some common misconceptions about GLP1 drugs like Ozempic, Wegovy, Mounjaro and others.
drug:wegovy
FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or OverweightThe FDA approved a new use for a drug to reduce the risk of serious heart problems in adults with cardiovascular disease and either obesity or overweight.FDAOffice of the Commissioner In great